ライフサイエンスコーパス: calicheamicin

1 ber of the nonchromoprotein enediyne family, calicheamicin.

2 al antibody conjugated to a cytotoxic agent, calicheamicin.

3 dy linked to the potent antitumor antibiotic calicheamicin.

4 aked DNA was markedly different from that of calicheamicin.

5 a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent.

6 a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent.

7 rase CalG4, provides growing support for the calicheamicin aminopentose pathway as a TDP-sugar-depend

8 prior studies on the base specificity of the calicheamicin aminopentosyltransferase CalG4, provides g

9 ependent increase in M1G in DNA treated with calicheamicin and bleomycin, oxidizing agents known to p

10 Other conjugates of calicheamicin and conjugates of potent tubulin poisons (

11 A cleavage by naturally occurring enediynes [calicheamicin and esperamicin), non-enediyne small molec

12 tic oligosaccharide moiety of the antibiotic calicheamicin and the head-to-head dimer of this oligosa

13 ns, more than 70 differentially glycosylated calicheamicin and vancomycin variants are reported.

14 stinct natural product biosynthetic pathways-calicheamicin and vancomycin-readily catalyze reversible

15 CD22 monoclonal antibody [mAb] conjugated to calicheamicin) and its in vivo use to characterize the k

16 nti-CD22 monoclonal antibody conjugated with calicheamicin [anti-CD22/cal]) efficiently depleted B ce

17 y be a key precursor to the enediyne core of calicheamicin, as it is the only programmed, enzyme-boun

18 We now present evidence that calicheamicin bends its DNA targets.

19 8, the polyketide synthase (PKS) involved in calicheamicin biosynthesis, facilitating the unambiguous

20 some insight into the elusive early steps of calicheamicin biosynthesis.

21 udy of the UGDH homolog CalS8 encoded by the calicheamicin biosynthetic gene is reported and represen

22 ng an intercalating anthranilate moiety, and calicheamicin, both groove binders, were found to cleave

23 irs in Escherichia coli; (ii) the C-1027 and calicheamicin cognate PKSE-TEs in Streptomyces lividans

24 e studied patients who received an anti-CD22/calicheamicin conjugate (inotuzumab ozogamicin; InO) to

25 argeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed b

26 Consistent with previous observations, calicheamicin damage at the 3'-end of a purine tract (po

27 zing fermentation conditions to generate new calicheamicin derivatives.

28 s containing AGGA and ACAA binding sites for calicheamicin did not possess intrinsic curvature.

29 3-targeted immunoconjugate of N-acetyl-gamma-calicheamicin dimethyl hydrazide [CalichDMH], a potent D

30 eptin) and three from 10-membered producers (calicheamicin, dynemicin, and esperamicin), reveals a cl

31 It was also observed that binding of calicheamicin epsilon to a 273 bp construct with phased

32 Binding of calicheamicin epsilon, the aromatized form of the parent

33 rgeted chemotherapy with immunoconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Myl

34 ies specific for tumour-associated antigens, calicheamicin exerts strong antigen-specific anti-tumour

35 of this family of antitumor agents, N-acetyl calicheamicin [Formula: see text], have a proven success

36 Calicheamicin gamma 1 (1) was found to be less efficient

37 (T-C-C-T).(A-G-G-A) sequence as a preferred calicheamicin gamma 1I binding site and established the

38 Calicheamicin gamma 1I binds to the DNA minor groove wit

39 Calicheamicin gamma 1I binds to the minor groove of the

40 Calicheamicin gamma 1I is an enediyne antibiotic possess

41 Sequence-specific binding of calicheamicin gamma 1I to the (T-C-C-T).(A-G-G-A) contai

42 ther enediynes, such as neocarzinostatin and calicheamicin gamma 1I under similar reaction conditions

43 We report on the solution structure of the calicheamicin gamma 1I-DNA hairpin duplex complex contai

44 medicine after the Second World War, so did calicheamicin gamma(1) (I) , and other highly potent nat

45 e first and the last of which carry the same calicheamicin gamma(1) (I) -derived payload.

46 A notable exception is calicheamicin gamma(1) (I), a potent antitumor compound

47 ts of the highly substituted benzene ring in calicheamicin gamma(1) (I).

48 Calicheamicin gamma(1) and related natural products are

49 , the complex strained enediyne structure of calicheamicin gamma(1) presents significant challenges i

50 ed in this article: endiandric acids (1982), calicheamicin gamma(1)(I) (1992), Taxol (1994), and brev

51 nthetic enzymes for the 10-membered enediyne calicheamicin gamma(1)(I), including the elusive beta-ke

52 n epsilon, the aromatized form of the parent calicheamicin gamma(1)(I), to oligonucleotide constructs

53 e enediyne antibiotics, neocarzinostatin and calicheamicin gamma(1)(I), was exploited in control stud

54 ctive, efficient, and modular alternative to calicheamicin gamma(1), this technology offers the poten

55 that facilitates cellular uptake of a toxic calicheamicin-gamma(1) derivative, induces complete remi

56 D33 antibody to facilitate uptake of a toxic calicheamicin-gamma(1) derivative.

57 r to facilitate cellular uptake of the toxic calicheamicin-gamma(1) derivative.

58 induced by GO, and, to a lesser degree, free calicheamicin-gamma(1).

59 We demonstrate here that the enediyne calicheamicin gamma1I, a strand-breaking agent specific

60 phore of (DA) and the carbohydrate domain of calicheamicin gamma1I.

61 A damage produced by the enediyne antibiotic calicheamicin gammaII in nucleosomes reconstituted onto

62 Here, we report structures of all four calicheamicin glycosyltransferases (CalG1, CalG2, CalG3,

63 gamicin, a CD22 monoclonal antibody bound to calicheamicin, has resulted in marrow CR rates of 55% an

64 lishes CalE10 as the key oxidase involved in calicheamicin hydroxylamino glycoside formation.

65 Phase I trials of a calicheamicin immunoconjugate for treatment of acute mye

66 ences and the effects of DNA conformation on calicheamicin-induced DNA cleavage suggest that sequence

67 Calicheamicin is a hydrophobic enediyne antibiotic that

68 Calicheamicin is a potent cytotoxic agent that causes do

69 conjugate of an anti-CD33 antibody linked to calicheamicin, is effective monotherapy for CD33(+) rela

70 Comparison of the calicheamicin locus with the locus encoding the chromopr

71 mage produced by esperamicin C, an analog of calicheamicin missing the terminal sugar-aromatic ring i

72 gamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients wi

73 The discovery of the heptaene in the calicheamicin system promotes a more convergent model fo

74 (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the e

75 the hypothesis that the preferred targets of calicheamicin, the 3' ends of oligopurine tracts, are ch

76 ere, we describe the first successful use of calicheamicin theta(I)1 for targeted chemotherapy in a c

77 el, rationally designed enediyene antibiotic calicheamicin theta(I)1 of exceptionally high cytotoxic

78 is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells.

79 Given the sensitivity of calicheamicin to local DNA conformation, this observatio

80 Calicheamicin unexpectedly caused 1'-oxidation at a low